Multiple Myeloma: A Study of Denosumab in Multiple Myeloma Patients With Renal InsufficiencyResearch Question:
How safe is and what is the tolerability of denosumab in newly diagnosed or relapsed
multiple myeloma patients?
Basic Study Information
Purpose:Location: Cancer Center
If you decide to participate in this study you will receive denosumab every 4 weeks
for a total of 12 cycles.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02833610?term=15-571&rank=1
Study Reference #: UMMY17073
Lead Researcher (Principal Investigator)
Lead Researcher: Brea Lipe
Study Contact InformationStudy Coordinator: Andrew Bui
Phone: (585) 276-4405
Additional Study Details
Learn More About These Conditions
More information about Multiple Myeloma
Trial Not Found
The study you are looking for is not active at this time.
Return to Search